JP2017523206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523206A5 JP2017523206A5 JP2017505606A JP2017505606A JP2017523206A5 JP 2017523206 A5 JP2017523206 A5 JP 2017523206A5 JP 2017505606 A JP2017505606 A JP 2017505606A JP 2017505606 A JP2017505606 A JP 2017505606A JP 2017523206 A5 JP2017523206 A5 JP 2017523206A5
- Authority
- JP
- Japan
- Prior art keywords
- solid dispersion
- ibrutinib
- formulation
- polymer matrix
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 32
- 239000007962 solid dispersion Substances 0.000 claims 29
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 25
- 229960001507 ibrutinib Drugs 0.000 claims 25
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 24
- 229920000642 polymer Polymers 0.000 claims 20
- 238000009472 formulation Methods 0.000 claims 16
- 239000011159 matrix material Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
- 239000007921 spray Substances 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims 5
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 3
- 229960003943 hypromellose Drugs 0.000 claims 3
- -1 ibrutinib compound Chemical class 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical group N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 239000007963 capsule composition Substances 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 229920000578 graft polymer Polymers 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims 1
- 230000035839 C max Effects 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229960000913 Crospovidone Drugs 0.000 claims 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229940023144 SODIUM GLYCOLATE Drugs 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- YOEWQQVKRJEPAE-UHFFFAOYSA-L Suxamethonium chloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- 230000001058 adult Effects 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 235000020828 fasting Nutrition 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium;2-hydroxyacetate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008137 solubility enhancer Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Claims (18)
- 固体分散イブルチニブを含む固体分散医薬組成物であって、イブルチニブが式(I)の化合物である、固体分散医薬組成物。
- 前記固体分散イブルチニブが噴霧乾燥イブルチニブ組成物である、請求項1に記載の固体分散医薬組成物。
- 前記噴霧乾燥イブルチニブ組成物が1つ以上の溶解促進剤内に分散されているイブルチニブを含む、請求項2に記載の固体分散医薬組成物。
- 前記溶解促進剤がポリマーマトリックスであって、前記ポリマーマトリックスが1つ以上のポリマーを含む、請求項3に記載の固体分散医薬組成物。
- 前記噴霧乾燥イブルチニブ組成物が、ポリマーマトリックス内に分散された1〜90重量/重量%のイブルチニブを含む、請求項4に記載の固体分散医薬組成物。
- 前記ポリマーマトリックス中の前記ポリマーが直鎖ポリマー、架橋ポリマー、コポリマー、グラフトポリマーまたはこれらの任意の組み合わせである、請求項4に記載の固体分散医薬組成物。
- 前記ポリマーが約2,000〜約500,000ダルトン、約100,000〜約200,000ダルトン、約200,000〜約300,000ダルトンまたは約400,000〜約500,000ダルトンの範囲の分子量を有する、請求項4に記載の固体分散医薬組成物。
- ポリマーマトリックスのポリマーは、ヒドロキシプロピルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルメチルセルロース(HPMC)、メチルセルロースポリマー、ヒドロキシエチルセルロース、カルボキシメチルセルロースナトリウム、カルボキシメチレンヒドロキシエチルセルロース及び/もしくはカルボキシメチルヒドロキシエチルセルロース、アクリルポリマー、ヒドロキシプロピルセルロースアセテートサクシネート、ヒドロキシプロピルメチルセルロースフタレート、セルロースアセテートフタレート、ヒドロキシプロピルメチルセルロースアセテート、ヒドロキシプロピルメチルセルロースアセテートサクシネート(HPMCAS)、もしくはこれらのブレンド、またはこれらの混合物から選択される、請求項4に記載の固体分散医薬組成物。
- 請求項1乃至8の何れか1つに記載の固体分散医薬組成物及び薬学的に許容される賦形剤を含む、固体分散体製剤。
- 前記賦形剤が約10重量/重量%〜約50重量/重量%の量で存在する、請求項9に記載の固体分散体製剤。
- 賦形剤は希釈剤、崩壊剤、界面活性剤またはこれらの組み合わせから選択される、請求項9に記載の固体分散体製剤。
- 前記製剤が1つ以上の滑剤を更に含む、請求項9に記載の固体分散体製剤。
- 前記製剤が1つ以上の滑沢剤を更に含む。請求項9に記載の固体分散体製剤。
- 前記製剤が、
a)約5重量/重量%〜約50重量/重量%の20%〜80%活性な噴霧乾燥イブルチニブと、
b)約10重量/重量%〜約75重量/重量%のラクトースと、
c)約5重量/重量%〜約50重量/重量%の微結晶セルロースと、
d)約0重量/重量%〜約15重量/重量%のクロスカルメロースナトリウムと、
e)約0.25重量/重量%〜約2.5重量/重量%のステアリン酸マグネシウムとを含み、
前記20%〜80%活性な噴霧乾燥イブルチニブが、ポリマーマトリックス内に分散された約20重量/重量%〜約80重量/重量%のイブルチニブを含む噴霧乾燥イブルチニブ組成物であり、前記ポリマーマトリックスがヒプロメロースである、請求項9に記載の固体分散体製剤。 - 固体分散体製剤であって、
a)式(I)の化合物である、約10重量/重量%〜約25重量/重量%の20%〜50%活性な噴霧乾燥イブルチニブと、
c)約24重量/重量%〜約26重量/重量%の微結晶セルロースと、
d)約5重量/重量%〜約7重量/重量%のクロスカルメロースナトリウムと、
e)約0重量/重量%〜約2重量/重量%のコロイド状二酸化ケイ素と、
f)約0重量/重量%〜約1重量/重量%のステアリン酸マグネシウムとを含み、
前記20%〜50%活性な噴霧乾燥イブルチニブが、ポリマーマトリックス内に分散された約20重量/重量%〜約50重量/重量%のイブルチニブを含む噴霧乾燥イブルチニブ組成物であり、前記ポリマーマトリックスはヒドロキシプロピルメチルセルロースアセテートサクシネート(HPMCAS)、ポリビニルカプロラクタム−ポリビニルアセテート−ポリエチレングリコールグラフトコポリマー(SOLUPLUS(登録商標))、またはそれらの混合物である、固体分散体製剤。 - 固体分散体製剤であって、
a)約30重量/重量%〜約50重量/重量%の請求項1乃至8の何れか1つに記載の固体分散医薬組成物と、
b)微結晶セルロース、コロイド状二酸化ケイ素、グリコール酸ナトリウムデンプン、およびステアリルフマル酸ナトリウムを含む、約20重量/重量%〜約25重量/重量%の賦形剤混合物と、
c)約0.2重量/重量%〜約0.8重量/重量%のステアリルフマル酸ナトリウムと、
d)約25重量/重量%〜約35重量/重量%のクロスポビドンとを含む、固体分散体製剤。 - 固体分散体製剤であって、
a)式(I)の化合物である、約5重量/重量%〜約50重量/重量%の20%〜80%活性な噴霧乾燥イブルチニブと、
c)約5重量/重量%〜約50重量/重量%の微結晶セルロースと、
d)約0重量/重量%〜約15重量/重量%のクロスカルメロースナトリウムと、
e)約0.25重量/重量%〜約2.5重量/重量%のステアリン酸マグネシウムとを含み、
前記20%〜80%活性な噴霧乾燥イブルチニブが、ポリマーマトリックス内に分散された約20重量/重量%〜約80重量/重量%のイブルチニブを含む噴霧乾燥イブルチニブ組成物であり、前記ポリマーマトリックスはヒプロメロースであり、
前記固体分散体製剤は、固体分散組成物中にはないイブルチニブを含むカプセル製剤と比較して、2〜25倍増の薬物曝露を提供する、固体分散体製剤。 - 固体分散体製剤であって、
a)式(I)の化合物である、約5重量/重量%〜約50重量/重量%の20%〜80%活性な噴霧乾燥イブルチニブと、
c)約5重量/重量%〜約50重量/重量%の微結晶セルロースと、
d)約0重量/重量%〜約15重量/重量%のクロスカルメロースナトリウムと、
e)約0.25重量/重量%〜約2.5重量/重量%のステアリン酸マグネシウムとを含み、
前記20%〜80%活性な噴霧乾燥イブルチニブが、ポリマーマトリックス内に分散された約20重量/重量%〜約80重量/重量%のイブルチニブを含む噴霧乾燥イブルチニブ組成物であり、前記ポリマーマトリックスはヒプロメロースであり、
前記固体分散体製剤は、固体分散組成物中にはないイブルチニブを含むカプセル製剤と比較して、絶食状態の健康なヒト成人の集団に観察されたイブルチニブの最大平均血漿濃度(C max )の2〜25倍の増加を提供する、固体分散体製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462034353P | 2014-08-07 | 2014-08-07 | |
US62/034,353 | 2014-08-07 | ||
PCT/US2015/044258 WO2016022942A1 (en) | 2014-08-07 | 2015-08-07 | Novel formulations of a bruton's tyrosine kinase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017523206A JP2017523206A (ja) | 2017-08-17 |
JP2017523206A5 true JP2017523206A5 (ja) | 2018-09-20 |
Family
ID=55264642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017505606A Pending JP2017523206A (ja) | 2014-08-07 | 2015-08-07 | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
Country Status (13)
Country | Link |
---|---|
US (4) | US9545407B2 (ja) |
EP (1) | EP3193877A4 (ja) |
JP (1) | JP2017523206A (ja) |
KR (1) | KR20170033358A (ja) |
CN (1) | CN106573002A (ja) |
AU (1) | AU2015300798A1 (ja) |
BR (1) | BR112017002231A2 (ja) |
CA (1) | CA2955747A1 (ja) |
IL (1) | IL250085A0 (ja) |
MX (1) | MX2017001671A (ja) |
RU (1) | RU2017106795A (ja) |
SG (1) | SG11201700849XA (ja) |
WO (1) | WO2016022942A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
CN110354132A (zh) | 2012-06-04 | 2019-10-22 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
CN106573002A (zh) * | 2014-08-07 | 2017-04-19 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂的新型制剂 |
TW202315634A (zh) | 2015-03-03 | 2023-04-16 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
SG11201707989PA (en) * | 2015-04-06 | 2017-10-30 | Janssen Pharmaceutica Nv | Compositions containing ibrutinib |
CA3008338A1 (en) * | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
TWI782982B (zh) * | 2017-04-24 | 2022-11-11 | 美商薩沐斯醫療公司 | Hsp90抑制劑口服調配物及相關方法 |
CN107014943B (zh) * | 2017-06-07 | 2018-08-21 | 福建省微生物研究所 | 一种依鲁替尼对映异构体的检测方法 |
CA3067723A1 (en) * | 2017-06-30 | 2019-01-03 | Onxeo | New oral formulations of belinostat |
EP3650025A4 (en) | 2017-07-04 | 2021-04-28 | Jiangsu Hengrui Medicine Co., Ltd. | PHARMACEUTICAL COMPOSITION AND METHOD FOR MANUFACTURING THEREOF |
US11478459B2 (en) * | 2017-08-11 | 2022-10-25 | Merck Patent Gmbh | Pharmaceutical preparation |
WO2019058386A1 (en) | 2017-09-19 | 2019-03-28 | Cipla Limited | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING IMPROVED BIOAVAILABILITY |
WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | NEW FORMS OF IBRUTINIB |
WO2019091438A1 (zh) * | 2017-11-10 | 2019-05-16 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 |
CZ2017787A3 (cs) * | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
CA3089537A1 (en) | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
MX2020011527A (es) | 2018-05-03 | 2021-02-26 | Juno Therapeutics Inc | Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa. |
CN112292117A (zh) | 2018-06-15 | 2021-01-29 | 詹森药业有限公司 | 包含依鲁替尼的配制品/组合物 |
CA3108065A1 (en) * | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
CA3149182A1 (en) * | 2019-09-23 | 2021-04-01 | Bionomics Limited | Therapeutic formulations and uses thereof |
CA3163053A1 (en) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Amorphous kinase inhibitor formulations and methods of use thereof |
EP4084779A1 (en) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
EP4142699A1 (en) * | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
CN111617028A (zh) * | 2020-07-14 | 2020-09-04 | 扬子江药业集团江苏紫龙药业有限公司 | 一种含伊布替尼的口服制剂及制备方法 |
US11529351B2 (en) * | 2021-01-21 | 2022-12-20 | Xspray Pharma Ab | Fast dissolving pharmaceutical compositions |
CA3210001A1 (en) * | 2021-03-03 | 2022-09-09 | Oakwood Laboratories, Llc | Microsphere formulations comprising btk inhibitors and methods for making and using the same |
CN113509443B (zh) * | 2021-07-14 | 2023-04-11 | 药源生物科技(启东)有限公司 | 一种含soluplus的固分体及其制备方法 |
WO2023104808A1 (en) * | 2021-12-10 | 2023-06-15 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
CN115054603A (zh) * | 2022-06-20 | 2022-09-16 | 上海宣泰医药科技股份有限公司 | 依鲁替尼药物组合物及其制备方法和药物制剂 |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3303707A1 (de) | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
PL335685A1 (en) | 1997-03-19 | 2000-05-08 | Basf Ag | Pyrrole[2,3-d]pyrimidines and their application as inhibitors of tyrosine kinase |
ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
EP1039909B1 (en) * | 1997-12-31 | 2002-10-09 | Choongwae Pharma Corporation | Method of production and composition of an oral preparation of itraconazole |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
ATE269295T1 (de) | 1998-04-17 | 2004-07-15 | Parker Hughes Inst | Btk inhibitoren und verfahren zur identifizierung und verwendung |
US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DK1212327T3 (da) | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
JP5036112B2 (ja) | 1999-10-06 | 2012-09-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | チロシンキナーゼのインヒビターとして有益な複素環化合物 |
AU4508601A (en) | 1999-11-30 | 2001-06-18 | Parker Hughes Institute | Inhibitors of collagen-induced platelet aggregation |
EP1246829A1 (en) | 1999-12-17 | 2002-10-09 | Ariad Pharmaceuticals, Inc. | Novel heterocycles |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
HUP0303656A3 (en) | 2000-10-23 | 2006-03-28 | Bristol Myers Squibb Co | Modulators of bruton's tyrosine kinase, their identification and use |
AU2002232492A1 (en) | 2000-12-06 | 2002-06-18 | Pharmacia Corporation | Rapidly dispersing pharmaceutical composition comprising effervescent agents |
WO2002067893A2 (en) * | 2001-02-27 | 2002-09-06 | Astrazeneca Ab | Pharmaceutical formulation comprising bicalutamide |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
US20030114467A1 (en) | 2001-06-21 | 2003-06-19 | Shakespeare William C. | Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof |
CA2450777C (en) | 2001-08-10 | 2013-04-09 | Novartis Ag | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
JP2005502861A (ja) | 2001-08-10 | 2005-01-27 | サイミックス テクノロジーズ, インコーポレイテッド | 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム |
WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
JP4391237B2 (ja) | 2001-11-21 | 2009-12-24 | サネシス ファーマシューティカルズ, インコーポレイテッド | リガンド発見のための方法 |
US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
JP2005536533A (ja) | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾイミダゾール化合物 |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
WO2005000197A2 (en) | 2003-04-11 | 2005-01-06 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
ATE531368T1 (de) * | 2003-08-29 | 2011-11-15 | Veloxis Pharmaceuticals As | Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung |
US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
SG132683A1 (en) | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
AU2005228845A1 (en) | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
ITMI20041314A1 (it) | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
KR20070063562A (ko) | 2004-09-28 | 2007-06-19 | 얀센 파마슈티카 엔.브이. | 치환 디피페리딘 ccr2 길항제 |
CA2587192A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
AU2006222365B2 (en) | 2005-03-07 | 2011-07-14 | Bayer Healthcare Llc | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
KR101357524B1 (ko) | 2005-03-10 | 2014-02-03 | 질레드 코네티컷 인코포레이티드 | 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법 |
WO2006124462A2 (en) | 2005-05-13 | 2006-11-23 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
EP1957491A2 (en) | 2005-11-12 | 2008-08-20 | Boehringer Ingelheim International GmbH | Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors |
RU2008133161A (ru) | 2006-01-13 | 2010-02-20 | Фармасайкликс, Инк. (Us) | Ингибиторы тирозин киназ и их применение |
US20090317836A1 (en) | 2006-01-30 | 2009-12-24 | The Scripps Research Institute | Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject |
JP2009530415A (ja) * | 2006-03-20 | 2009-08-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
EP2557080A1 (en) | 2006-04-04 | 2013-02-13 | The Regents of The University of California | Method for identifying pI3-kinase antagonists |
EP2027087A2 (en) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
NL2000640C2 (nl) | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2874756C (en) | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20090010911A1 (en) | 2007-04-06 | 2009-01-08 | Iowa State University Research Foundation, Inc. | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities |
TWI475996B (zh) | 2007-10-19 | 2015-03-11 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
EP2205564B1 (en) | 2007-10-23 | 2014-07-30 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
CA2720671A1 (en) | 2008-04-14 | 2009-10-22 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
MX2011001005A (es) | 2008-07-29 | 2011-09-01 | Frontier Scient Inc | Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento. |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
WO2010126960A1 (en) | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
EP2578585B1 (en) | 2010-05-31 | 2016-07-20 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
NZ627709A (en) | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
CA2807051A1 (en) | 2010-08-10 | 2012-02-16 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
US8541391B2 (en) | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
US8501484B2 (en) | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
MX2011004759A (es) | 2011-05-04 | 2012-11-21 | Senosiain S A De C V Lab | Nuevas formas solidas de antibioticos. |
BR112013028846B1 (pt) | 2011-05-17 | 2021-12-07 | Principia Biopharma Inc | Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica |
WO2013012959A1 (en) | 2011-07-18 | 2013-01-24 | Tokai Pharmaceuticals, Inc. | Novel compositions and methods for treating prostate cancer |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
PL2802314T3 (pl) * | 2012-01-13 | 2021-06-14 | Xspray Microparticles Ab | Sposób wytwarzania stabilnych, amorficznych hybrydowych nanocząstek zawierających co najmniej jeden inhibitor kinazy białkowej i co najmniej jeden polimerowy składnik stabilizujący i tworzący macierz |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
JP5514256B2 (ja) | 2012-05-18 | 2014-06-04 | 株式会社東芝 | 磁気記憶素子及びその製造方法 |
CN110354132A (zh) * | 2012-06-04 | 2019-10-22 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
CN103121999A (zh) | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
CN104854107A (zh) | 2012-11-15 | 2015-08-19 | 药品循环公司 | 作为激酶抑制剂的吡咯并嘧啶化合物 |
US20140377258A1 (en) | 2013-05-30 | 2014-12-25 | Infinity Pharmaceuticals, Inc. | Treatment Of Cancers Using PI3 Kinase Isoform Modulators |
US20160067241A1 (en) | 2013-06-13 | 2016-03-10 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
AR097204A1 (es) | 2013-08-02 | 2016-02-24 | Pharmacyclics Inc | Métodos de tratamiento de tumores sólidos |
WO2015034478A1 (en) | 2013-09-04 | 2015-03-12 | Halliburton Energy Services, Inc. | Scale-inhibiting cocrystals for treatment of a subterranean formation |
WO2015038887A1 (en) | 2013-09-12 | 2015-03-19 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
MX2016005283A (es) | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
WO2015071432A1 (en) | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
CA2933900A1 (en) | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Formulations and methods for targeted ocular delivery of therapeutic agents |
CN106008515A (zh) | 2014-01-29 | 2016-10-12 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
US20150231077A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
WO2015127261A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
US20150267752A1 (en) | 2014-03-19 | 2015-09-24 | Roller Bearing Company Of America, Inc. | Bearing outer race having a radially inwardly biased seal |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
MX2016012419A (es) | 2014-03-27 | 2016-11-30 | Perrigo Api Ltd | Formas solidas de ibrutinib y procesos para la produccion de las mismas. |
CN105085529A (zh) | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US20150110871A1 (en) | 2014-06-02 | 2015-04-23 | David Wong | Gastric retentive tablet compositions |
US20160008777A1 (en) | 2014-07-09 | 2016-01-14 | Novotec Consulting Inc. | Pharmaceutical compounding kit |
PT107846B (pt) | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
WO2016020697A1 (en) | 2014-08-06 | 2016-02-11 | Cipla Limited | Pharmaceutical compositions of polymeric nanoparticles |
CN106573002A (zh) * | 2014-08-07 | 2017-04-19 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂的新型制剂 |
EP3180343A1 (en) | 2014-08-14 | 2017-06-21 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
ES2727952T3 (es) | 2014-10-01 | 2019-10-21 | Ratiopharm Gmbh | Sal de adición de ácido de ibrutinib |
CN104523695A (zh) | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
CN105640961A (zh) | 2014-11-18 | 2016-06-08 | 山东瑞禾医药科技有限公司 | 一种含依鲁替尼的药物组合物 |
WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
US20150224060A1 (en) | 2015-01-03 | 2015-08-13 | David Wong | Gastric retentive tablet compositions |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
EP3265092A4 (en) | 2015-03-03 | 2018-07-18 | Dr. Reddy's Laboratories Ltd. | Polymorphs of ibrutinib |
TW202315634A (zh) * | 2015-03-03 | 2023-04-16 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
US10377758B2 (en) | 2015-04-02 | 2019-08-13 | Ratiopharm Gmbh | Co-crystals of ibrutinib with carboxylic acids |
SG11201707989PA (en) | 2015-04-06 | 2017-10-30 | Janssen Pharmaceutica Nv | Compositions containing ibrutinib |
CN105294696A (zh) | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
CN105440040B (zh) | 2015-12-23 | 2018-03-13 | 浙江京新药业股份有限公司 | 依鲁替尼的纯化方法 |
CN105646484A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 晶型b及制备方法 |
CN105646498A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
CN105646499A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型g及制备方法 |
CN106619643A (zh) | 2016-11-11 | 2017-05-10 | 上海雅本化学有限公司 | 一种含依鲁替尼的药物组合物 |
-
2015
- 2015-08-07 CN CN201580043327.XA patent/CN106573002A/zh active Pending
- 2015-08-07 SG SG11201700849XA patent/SG11201700849XA/en unknown
- 2015-08-07 KR KR1020177004064A patent/KR20170033358A/ko unknown
- 2015-08-07 US US14/821,290 patent/US9545407B2/en active Active
- 2015-08-07 JP JP2017505606A patent/JP2017523206A/ja active Pending
- 2015-08-07 WO PCT/US2015/044258 patent/WO2016022942A1/en active Application Filing
- 2015-08-07 AU AU2015300798A patent/AU2015300798A1/en not_active Abandoned
- 2015-08-07 RU RU2017106795A patent/RU2017106795A/ru not_active Application Discontinuation
- 2015-08-07 MX MX2017001671A patent/MX2017001671A/es unknown
- 2015-08-07 EP EP15829513.9A patent/EP3193877A4/en not_active Withdrawn
- 2015-08-07 BR BR112017002231-1A patent/BR112017002231A2/pt not_active Application Discontinuation
- 2015-08-07 CA CA2955747A patent/CA2955747A1/en not_active Abandoned
-
2016
- 2016-12-06 US US15/370,535 patent/US20170079981A1/en not_active Abandoned
-
2017
- 2017-01-12 IL IL250085A patent/IL250085A0/en unknown
- 2017-03-17 US US15/462,444 patent/US20180028537A1/en active Granted
-
2018
- 2018-10-19 US US16/165,895 patent/US20190282578A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017523206A5 (ja) | ||
RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
WO2017140254A1 (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
AU2012340759C1 (en) | Pharmaceutical formulations | |
JP2017525712A5 (ja) | ||
RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
KR101526625B1 (ko) | 벤조아제핀을 포함하는 의약 고형 제제 및 그의 제조 방법 | |
JP2005320354A5 (ja) | ||
CA2623018A1 (en) | Pharmaceutical compositions of telmisartan | |
KR20160142342A (ko) | 무정형 소포스부비르를 포함하는 고체 조성물 | |
JP2016188181A (ja) | ミラベグロン含有放出制御錠剤 | |
JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
KR102333463B1 (ko) | 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법 | |
JP2016530238A5 (ja) | ||
ES2674811T3 (es) | Composiciones estables de fesoterodina | |
JP2016512845A (ja) | ソバプレビル錠剤 | |
WO2019142207A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
WO2016012898A1 (en) | Oral pharmaceutical composition of lurasidone | |
BR112014026040B1 (pt) | Comprimido de liberação sustentada que contém levodropropizina | |
WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
JP2015504913A (ja) | 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法 | |
KR101524264B1 (ko) | 발사르탄 함유 경구용 약학 조성물 | |
US20180064653A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
US20140377346A1 (en) | Bosentan controlled release oral preparation | |
US10391178B2 (en) | Premix of crystalline raltegravir potassium salt and a process for the preparation thereof |